Submission is supported by 24-week results from the Phase 3b APEX study in adults with active psoriatic arthritis treated ...

The submission is supported by Phase IIIb APEX trial results showing Tremfya reduced symptoms and inhibited structural progression in biologic-naïve patients with active psoriatic arthritis.

Understand how psoriatic arthritis increases heart disease risk through inflammation. Learn management tips for heart health, from lifestyle changes to medication discussions.

HORSHAM, PA — Johnson & Johnson (NYSE: JNJ) has submitted a supplemental Biologics License Application (sBLA) to the U.S.

While Stelara is used in fewer indications than Humira, it commands a large market share in its therapeutic areas, most ...

Lower muscle volume, and more fat stored in the muscle, are seen linked to higher risk for disease and comorbidities.

Tildrakizumab is an interleukin-23 antagonist approved under the brand name Ilumya for the treatment of plaque psoriasis.

Both men and women with psoriasis are equally at risk for developing psoriatic arthritis (PsA)—a chronic inflammatory ...

Below are the ratings of the most accurate analysts for three high-yielding stocks in the health care sector. Barclays ...

Self-care methods for psoriatic arthritis (PsA) include staying active with gentle exercises, getting enough sleep, and ...

Dealing with the itchy, scaly patches that come with psoriasis is difficult enough. But having psoriasis puts you at risk of developing psoriatic arthritis, an inflammatory condition that impacts the ...

With new systemic treatments now available for psoriatic disease, questions remain on the comparable efficacy and safety of these therapies.